Systematic reviews of treatment for inflammatory demyelinating neuropathy.
This review describes the progress made in preparing Cochrane systematic reviews of randomized controlled trials for Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and the demyelinating neuropathies associated with paraproteins. The discovery of antibodies against myelin and axolemmal glycolipids and proteins has not yet replaced the clinicopathological classification on which treatment trials have been based. Systematic reviews have endorsed the equivalence of plasma exchange (PE) and intravenous immunoglobulin (IVIg) and the lack of efficacy of steroids in GBS. Systematic reviews have also endorsed the value of steroids, PE and IVIg in CIDP but randomized controlled trials have only shown benefit from IVIg in MMN. There is a paucity of evidence concerning the efficacy of treatments in paraproteinaemic demyelinating neuropathy apartment from small trials showing short-term benefit from PE or IVIg. There is a lack of good quality controlled trials of immunosuppressive agents in any of these conditions. As the number of treatment trials increases, Cochrane systematic reviews will be an increasingly valuable resource for summarizing the evidence from randomised controlled trials on which to base clinical practice. They already demonstrate major deficiencies in the existing evidence base.
Hughes
R A C
RA
Cochrane Neuromuscular Disease Review Group, Guy's, King's and St Thomas' School of Medicine, Guy's Hospital, London, UK.
D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous; D010265:Paraproteinemias / Q000628:therapy; D010266:Paraproteins / Q000008:administration & dosage; D011129:Polyradiculoneuropathy / Q000276:immunology / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic
D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D010266:Paraproteins